サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1623479

埋め込み型ドラッグデリバリーデバイスの世界市場規模：製品別、用途別、技術別、エンドユーザー別、地域別範囲と予測

Global Implantable Drug Delivery Devices Market Size By Product, By Application, By Technology, By End-User And By Geographic Scope And Forecast

出版日
ページ情報
英文 202 Pages
納期
2～3営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
埋め込み型ドラッグデリバリーデバイスの世界市場規模：製品別、用途別、技術別、エンドユーザー別、地域別範囲と予測
出版日: 2024年08月03日
発行: Verified Market Research
ページ情報: 英文 202 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

埋め込み型ドラッグデリバリーデバイスの市場規模と予測

埋め込み型ドラッグデリバリーデバイスの市場規模は、2023年に255億2,000万米ドルと推計され、2024年から2031年にかけて7.25%のCAGRで成長し、2031年には403億5,000万米ドルに達すると予測されます。部位特異的な薬物投与を可能にする埋め込み型ドラッグデリバリーデバイスは、低濃度の薬物で効果的な送達を実現できる代替システムです。この機能により、患者のコンプライアンスを向上させながら、潜在的な副作用を最小限に抑えることができます。治療薬の持続的放出は、注射針を繰り返し刺す必要なく薬物や水分を投与するこれらの装置によって促進されます。埋め込み型ドラッグデリバリーデバイスにより、静脈注射のための入院が回避されます。

ポリマーまたは薬剤とポリマーの混合物で囲まれた薬剤リザーバーで構成されるこれらのデバイスは、体内の所望の部位に挿入されるとポリマーが分解し、あらかじめ決められた速度で薬剤を放出します。

埋め込み型ドラッグデリバリーデバイスの世界市場力学

埋め込み型ドラッグデリバリーデバイス市場を形成している主な市場力学

主な市場促進要因

慢性疾患の有病率の上昇：

がん、心血管疾患、糖尿病などの慢性疾患は、高齢化、不健康なライフスタイル、診断法の改善などの要因によって、世界中でますます流行しています。効果的な治療オプションに対する需要は、このような負担の増加によって高まっており、埋め込み型ドラッグデリバリーシステムは、制御された標的薬物放出のための貴重なツールとなっています。

技術の進歩：

材料科学、微細加工、生体工学の絶え間ない進歩により、より洗練された効果的な埋め込み型ドラッグデリバリーデバイスの開発が進んでいます。薬物放出の制御、生体適合性の向上、標的送達などの特徴は、こうした進歩によって可能となり、最終的に患者の転帰改善につながり、市場の成長を牽引しています。

低侵襲手術への注目の高まり：

回復時間が早く、患者の不快感が少ないことから、従来の手術よりも低侵襲な処置が好まれるようになっていることが、埋め込み型ドラッグデリバリー市場促進要因の大きな要因となっています。これらのデバイスは、経口薬や注射のような従来のドラッグデリバリー方法に代わる低侵襲の代替手段を提供し、患者と医療提供者の双方にとって魅力的な選択肢となっています。

主な課題

厳しい規制要件：

体内に異物を埋め込むことには固有のリスクが伴うため、埋め込み型ドラッグデリバリーシステムの承認プロセスは高度に規制されています。そのため、安全性、有効性、生体適合性を確保するための厳格な試験や臨床試験が必要となり、その結果、開発期間は長期化し、費用もかさみます。その結果、技術革新が著しく阻害され、患者の生命を救う治療法の提供が遅れる可能性があります。

開発・製造コストの高さ：

埋め込み型ドラッグデリバリーシステムは、複雑な技術が関与し、高品質の材料と高度な製造プロセスが必要なため、開発と製造に高いコストがかかることが多いです。このため、主要企業は多額の初期費用を負担することになり、収益性に影響を及ぼすとともに、特に中低所得国の患者にとっては、こうした技術へのアクセスが制限される可能性があります。

償還の課題と市場アクセス：

薬事承認後であっても、保険会社やヘルスケアプロバイダーからこれらの先端治療に対する十分な償還を確保することは困難です。このような制限は、患者の生命を変える可能性のある治療へのアクセスを妨げ、埋め込み型ドラッグデリバリーシステム市場の成長を阻害する可能性があります。さらに、医療制度や規制が異なる地域での市場参入は、この市場で事業を展開する企業にとってもう一つの障害となります。

主要動向

統合の進展と戦略的提携：

大規模な製薬企業や医療機器企業が、合併や買収、戦略的提携を通じて自社のポジションを強化しようとしているため、移植可能ドラッグデリバリー市場でも統合が進んでいます。こうした提携は、補完的な技術や専門知識を活用し、製品開発と市場開拓を加速させることを目的としています。

拡大するアプリケーションの探求：

埋め込み型ドラッグデリバリーシステムは、ホルモン補充療法、疼痛管理、避妊、がん治療など、従来のドラッグデリバリーにとどまらない幅広い治療への応用が模索されていました。このような用途の多様化が、市場の技術革新と投資の原動力となっています。

患者の利便性とコンプライアンスへの注目：

埋め込み型ドラッグデリバリーシステムは、頻繁な投与や投薬の必要性をなくすことで、患者のコンプライアンスと利便性を向上させる可能性を秘めていました。これは特に、長期にわたる薬物療法を必要とする慢性疾患の患者にとって有益でした。

目次

第1章 埋め込み型ドラッグデリバリーデバイスの世界市場：イントロダクション

  • 市場概要
  • 調査範囲
  • 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

  • データマイニング
  • バリデーション
  • 一次資料
  • データソース一覧

第4章 埋め込み型ドラッグデリバリーデバイスの世界市場展望

  • 概要
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
  • ポーターのファイブフォースモデル
  • バリューチェーン分析
  • 規制の枠組み

第5章 埋め込み型ドラッグデリバリーデバイスの世界市場：技術別

  • 概要
  • アクティブドラッグデリバリーデバイス
  • パッシブドラッグデリバリーデバイス
    • 生分解性
    • 非生分解性

第6章 埋め込み型ドラッグデリバリーデバイスの世界市場：製品別

  • 概要
  • 生体吸収性ステント
  • 避妊ドラッグデリバリーデバイス
  • 眼内ドラッグデリバリーデバイス
  • 冠動脈薬剤溶出ステント
  • ブラキセラピーシード
  • 薬物注入ポンプ

第7章 埋め込み型ドラッグデリバリーデバイスの世界市場：用途別

  • 概要
  • 心血管疾患
  • 腫瘍学
  • 糖尿病
  • 眼科
  • 自己免疫疾患
  • 避妊
  • その他

第8章 埋め込み型ドラッグデリバリーデバイスの世界市場：エンドユーザー別

  • 概要
  • 病院および診療所
  • 外来手術センター
  • 専門センター
  • その他

第9章 埋め込み型ドラッグデリバリーデバイスの世界市場：地域別

  • 概要
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • その他欧州
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • その他アジア太平洋地域
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 世界のその他の地域
    • 中東・アフリカ

第10章 埋め込み型ドラッグデリバリーデバイスの世界市場：競合情勢

  • 概要
  • 各社の市場シェア
  • ベンダー情勢
  • 主な発展戦略

第11章 企業プロファイル

  • Bayer
  • Boston Scientific
  • Medtronic
  • Merck & Co. Inc.
  • Allergan Inc.
  • Bausch And Lomb Inc.
  • Ithetis
  • Nucletron
  • Genetech Inc.
  • Theragenics

第12章 主な発展

  • 製品の上市／開発
  • 合併と買収
  • 事業拡大
  • パートナーシップと提携

第13章 付録

  • 関連調査
目次
Product Code: 23845

Implantable Drug Delivery Devices Market Size And Forecast

Implantable Drug Delivery Devices Market size is estimated at USD 25.52 Billion in 2023 and is projected to reach USD 40.35 Billion by 2031, growing at a CAGR of 7.25% from 2024 to 2031. Implantable drug delivery devices, which enable site-specific drug administration, are an alternative system capable of achieving effective delivery with lower drug concentrations. This capability allows for the minimization of potential side effects while increasing patient compliance. The sustained release of a therapeutic agent is facilitated by these devices, which administer drugs and fluids without the need for the repeated insertion of needles. Hospitalization for intravenous infusion is avoided by implantable drug delivery devices.

Consisting of a drug reservoir surrounded by a polymer or a drug-polymer mixture, these devices release the drug at a pre-determined rate as the polymer degrades upon insertion into a desired area in the body.

Global Implantable Drug Delivery Devices Market Dynamics

The key market dynamics that are shaping the Implantable Drug Delivery Devices Market include:

Key Market Drivers

Rising Prevalence of Chronic Diseases:

Chronic diseases like cancer, cardiovascular diseases, and diabetes are increasingly prevalent worldwide, driven by factors such as an aging population, unhealthy lifestyles, and improved diagnostics. The demand for effective treatment options is fueled by this rising burden, making implantable drug delivery systems a valuable tool for controlled and targeted drug release, potentially improving treatment efficacy and patient compliance.

Technological Advancements:

Continuous advancements in materials science, microfabrication, and bioengineering are leading to the development of more sophisticated and effective implantable drug-delivery devices. Features like controlled drug release, improved biocompatibility, and targeted delivery are enabled by these advancements, ultimately leading to better patient outcomes and driving market growth.

Growing Focus on Minimally Invasive Procedures:

The increasing preference for minimally invasive procedures over traditional surgeries due to faster recovery times and less patient discomfort is a significant driver for the Implantable Drug Delivery Devices Market. These devices offer a minimally invasive alternative to traditional drug delivery methods like oral medications or injections, making them an attractive option for both patients and healthcare providers.

Key Challenges

Stringent Regulatory Requirements:

Due to the inherent risks associated with implanting foreign objects in the body, the approval process for implantable drug delivery systems is highly regulated. This involves subjecting them to rigorous testing and clinical trials to ensure safety, efficacy, and biocompatibility, resulting in lengthy and expensive development timelines. Innovation can be significantly impeded, and the availability of life-saving treatments to patients may be delayed as a consequence.

High Cost of Development and Production:

Implantable drug delivery systems often incur high costs in development and manufacturing due to the involvement of complex technologies and the necessity for high-quality materials and advanced manufacturing processes. This leads to substantial upfront costs for companies, impacting their profitability and potentially restricting access to these technologies for patients, particularly in low- and middle-income countries.

Reimbursement Challenges and Market Access:

Even following regulatory approval, securing adequate reimbursement from insurance companies and healthcare providers for these advanced therapies can be challenging. This limitation can impede patient access to these potentially life-changing treatments, thereby hindering market growth for implantable drug delivery systems. Additionally, gaining market access in different regions with varying healthcare systems and regulations presents another obstacle for companies operating in this market.

Key Trends

Consolidation Being Witnessed and Strategic Partnerships:

Consolidation was being witnessed in the Implantable Drug Delivery Devices Market as larger pharmaceutical and medical device companies were being sought to strengthen their positions through mergers, acquisitions, and strategic partnerships. These collaborations aimed to leverage complementary technologies and expertise to accelerate product development and market penetration.

Exploration of Expanding Applications:

Implantable drug delivery systems were being explored for a wide range of therapeutic applications beyond traditional drug delivery, including hormone replacement therapy, pain management, contraception, and cancer treatment. This diversification of applications was driving innovation and investment in the market.

Focus on Patient Convenience and Compliance:

The potential to improve patient compliance and convenience was offered by implantable drug delivery systems by eliminating the need for frequent dosing or administration. This was particularly beneficial for patients with chronic conditions who required long-term medication therapy.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Implantable Drug Delivery Devices Market Regional Analysis

Here is a more detailed regional analysis of the Implantable Drug Delivery Devices Market:

North America

A well-established healthcare infrastructure, including advanced medical facilities and research institutions, fosters innovation and the adoption of implantable drug delivery technologies.

Stringent regulatory standards, particularly by the FDA, ensure rigorous evaluation and approval processes for implantable drug delivery devices, enhancing confidence in their safety and efficacy.

Substantial investments in research and development are attracted by the region is facilitating the development of cutting-edge implantable drug delivery technologies and thereby, driving market growth.

The demand for effective and long-term drug delivery solutions is driven by the rising burden of chronic diseases such as cancer, cardiovascular diseases, and diabetes in North America, further solidifying the region's dominance in the market.

Asia Pacific

Market growth is driven by increasing healthcare expenditure in countries like China and India.

Demand for long-term drug delivery solutions is boosted by the rising prevalence of chronic diseases in the region.

Market expansion is contributed to by technological advancements and the growing adoption of innovative medical devices.

The market in Asia Pacific is further propelled by government initiatives to improve healthcare infrastructure and access to advanced treatments.

Global Implantable Drug Delivery Devices Market: Segmentation Analysis

The Global Implantable Drug Delivery Devices Market is Segmented on the basis of Product, Application, Technology, End-User, and Geography.

Implantable Drug Delivery Devices Market, By Product

  • Bio-absorbable stents
  • Contraceptive Drug Delivery Devices
  • Intraocular Drug Delivery Devices
  • Coronary Drug Eluting Stents
  • Brachytherapy Seeds
  • Drug Infusion Pumps

Based on Product, the market is segmented into Bio-absorbable stents, Contraceptive Drug Delivery Devices, Intraocular Drug Delivery Devices, Coronary Drug Eluting Stents, Brachytherapy Seeds, and Drug Infusion Pumps. The highest market share in the Implantable Drug Delivery Devices Market is held by the coronary drug-eluting stents segment. This dominance is primarily attributed to the widespread prevalence of cardiovascular diseases worldwide, resulting in a substantial demand for effective treatment options such as drug-eluting stents. Advancements in stent technologies and procedural techniques further contribute to the segment's market dominance.

Implantable Drug Delivery Devices Market, By Application

  • Cardiovascular Diseases
  • Oncology
  • Diabetes
  • Ophthalmology
  • Autoimmune Diseases
  • Birth Control & Contraception
  • Others

Based on Application, the market is segmented into Cardiovascular Diseases, Oncology, Diabetes, Ophthalmology, Autoimmune Diseases, Birth Control & Contraception, and Others. The highest market share in the Implantable Drug Delivery Devices Market is held by the cardiovascular diseases segment. This dominance is primarily attributed to the significant prevalence of cardiovascular conditions globally, which necessitates effective and targeted drug delivery solutions. The segment's market leadership is further contributed to by continuous advancements in cardiovascular therapies and procedures.

Implantable Drug Delivery Devices Market, By Technology

  • Active Drug Delivery Device
  • Passive Drug Delivery Device
  • Biodegradable
  • Non-biodegradable

Based on Technology, the market is segmented into Active Drug Delivery Devices and Passive Drug Delivery Devices. From which, Passive drug eluting device technology is projected to hold a major revenue share in the Implantable Drug Delivery Devices Market. This dominance of the segment is attributable to the large-scale applications of passive drug-eluting solutions in the fields of oncology, cardiology, pain management, contraception, etc.

Implantable Drug Delivery Devices Market, By End-User

  • Hospitals & Clinics
  • Ambulatory Surgical Centers
  • Specialty Centers
  • Others

Based on End-User, the market is segmented into Hospitals & Clinics, Ambulatory Surgical Centers, Specialty Centers, and Others. The Implantable Drug Delivery Devices Market's highest market share is held by hospitals & clinics. This dominance is primarily attributed to the widespread utilization of these facilities for the diagnosis, treatment, and management of various medical conditions necessitating implantable drug delivery systems. Specialized departments and resources dedicated to implantable drug delivery within hospitals and clinics further contribute to their market leadership.

Key Players

  • The "Implantable Drug Delivery Devices Market" study report will provide valuable insight with an emphasis on the global market including some of the major players such as
  • Bayer, Boston Scientific, Medtronic, Merck & Co., Inc., Allergan, Inc., Bausch AndLomb, Inc., Ithetis, Nucletron, Genetech, Inc., Theragenics, Psivida, Kinamed, Inc., K2M, Inc., Mako Surgical Corp., and Varian Medical System.

Our market analysis includes a section specifically devoted to such major players, where our analysts give an overview of each player's financial statements, along with product benchmarking and SWOT analysis. Key development strategies, market share analysis, and market positioning analysis of the aforementioned players globally are also included in the competitive landscape section.

  • Implantable Drug Delivery Devices Market Recent Developments
  • In August 2022, the Onyx Frontier drug-eluting stent (DES) was launched by Medtronic, after receiving CE Mark approval. This stent features an innovative delivery system and is built upon the success of their previous DES products.
  • In February 2023, FDA approval was received by Boston Scientific for their Eluvia drug-eluting stent intended for the treatment of coronary artery disease. This stent employs a novel polymer designed to control drug release and potentially enhance patient outcomes.

TABLE OF CONTENTS

1 INTRODUCTION OF THE GLOBAL IMPLANTABLE DRUG DELIVERY DEVICES MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL IMPLANTABLE DRUG DELIVERY DEVICES MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis
  • 4.5 Regulatory Framework

5 GLOBAL IMPLANTABLE DRUG DELIVERY DEVICES MARKET, BY TECHNOLOGY

  • 5.1 Overview
  • 5.2 Active Drug Delivery Device
  • 5.3 Passive Drug Delivery Device
    • 5.3.1 Biodegradable
    • 5.3.2 Non-biodegradable

6 GLOBAL IMPLANTABLE DRUG DELIVERY DEVICES MARKET, BY PRODUCT

  • 6.1 Overview
  • 6.2 Bio-absorbable stents
  • 6.3 Contraceptive Drug Delivery Devices
  • 6.4 Intraocular Drug Delivery Devices
  • 6.5 Coronary Drug Eluting Stents
  • 6.6 Brachytherapy Seeds
  • 6.7 Drug Infusion Pumps

7 GLOBAL IMPLANTABLE DRUG DELIVERY DEVICES MARKET, BY APPLICATION

  • 7.1 Overview
  • 7.2 Cardiovascular Diseases
  • 7.3 Oncology
  • 7.4 Diabetes
  • 7.5 Ophthalmology
  • 7.6 Autoimmune Diseases
  • 7.7 Birth Control & Contraception
  • 7.8 Others

8 GLOBAL IMPLANTABLE DRUG DELIVERY DEVICES MARKET, BY END-USER

  • 8.1 Overview
  • 8.2 Hospitals & Clinics
  • 8.3 Ambulatory Surgical Centers
  • 8.4 Specialty Centers
  • 8.5 Others

9 GLOBAL IMPLANTABLE DRUG DELIVERY DEVICES MARKET, BY GEOGRAPHY

  • 9.1 Overview
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 U.K.
    • 9.3.3 France
    • 9.3.4 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Argentina
  • 9.6 Rest of the World
    • 9.6.1 Middle East And Africa

10 GLOBAL IMPLANTABLE DRUG DELIVERY DEVICES MARKET COMPETITIVE LANDSCAPE

  • 10.1 Overview
  • 10.2 Company Market Share
  • 10.3 Vendor Landscape
  • 10.4 Key Development Strategies

11 COMPANY PROFILES

  • 11.1 Bayer
    • 11.1.1 Overview
    • 11.1.2 Financial Performance
    • 11.1.3 Product Outlook
    • 11.1.4 Key Developments
  • 11.2 Boston Scientific
    • 11.2.1 Overview
    • 11.2.2 Financial Performance
    • 11.2.3 Product Outlook
    • 11.2.4 Key Developments
  • 11.3 Medtronic
    • 11.3.1 Overview
    • 11.3.2 Financial Performance
    • 11.3.3 Product Outlook
    • 11.3.4 Key Developments
  • 11.4 Merck & Co. Inc.
    • 11.4.1 Overview
    • 11.4.2 Financial Performance
    • 11.4.3 Product Outlook
    • 11.4.4 Key Developments
  • 11.5 Allergan Inc.
    • 11.5.1 Overview
    • 11.5.2 Financial Performance
    • 11.5.3 Product Outlook
    • 11.5.4 Key Developments
  • 11.6 Bausch And Lomb Inc.
    • 11.6.1 Overview
    • 11.6.2 Financial Performance
    • 11.6.3 Product Outlook
    • 11.6.4 Key Developments
  • 11.7 Ithetis
    • 11.7.1 Overview
    • 11.7.2 Financial Performance
    • 11.7.3 Product Outlook
    • 11.7.4 Key Developments
  • 11.8 Nucletron
    • 11.8.1 Overview
    • 11.8.2 Financial Performance
    • 11.8.3 Product Outlook
    • 11.8.4 Key Developments
  • 11.9 Genetech Inc.
    • 11.9.1 Overview
    • 11.9.2 Financial Performance
    • 11.9.3 Product Outlook
    • 11.9.4 Key Developments
  • 11.10 Theragenics
    • 11.10.1 Overview
    • 11.10.2 Financial Performance
    • 11.10.3 Product Outlook
    • 11.10.4 Key Developments

12 KEY DEVELOPMENTS

  • 12.1 Product Launches/Developments
  • 12.2 Mergers and Acquisitions
  • 12.3 Business Expansions
  • 12.4 Partnerships and Collaborations

13 Appendix

  • 13.1 Related Research